Last viewed:
TRVN
Prices are updated after-hours
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
(0.0% 1d)
(-28.5% 1m)
(-46.1% 1y)
(0.0% 2d)
(0.3% 3d)
(-4.8% 7d)
(7.35%
volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 6,961,984
http://www.trevenainc.com
Sec
Filling
|
Patents
| 24 employees
(US) Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
urine
nervous system
injection
Drugs
OLINVYK
(OLICERIDINE )
add to watch list
Paper trade
email alert is off
Press-releases
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
Published: 2024-04-01
(Crawled : 11:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -16.01%
| O: -11.52%
H: 0.0%
C: 0.0%
update
results
CustomerInsights.AI Announces Strategic Advisory Board Members for 2024
Published: 2024-02-21
(Crawled : 17:00)
- prnewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -30.96%
| O: -1.62%
H: 1.63%
C: 1.0%
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
Published: 2023-12-28
(Crawled : 19:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -44.56%
| O: 0.16%
H: 4.23%
C: 1.7%
million
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
Published: 2023-12-27
(Crawled : 14:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -44.26%
| O: 1.4%
H: 2.1%
C: -2.24%
million
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
Published: 2023-12-04
(Crawled : 12:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -32.82%
| O: -4.22%
H: 7.78%
C: 6.91%
trv045
presentation
meeting
Trevena Awarded OLINVYK Agreement with Premier, Inc.
Published: 2023-12-04
(Crawled : 12:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -32.82%
| O: -4.22%
H: 7.78%
C: 6.91%
PINC
|
$20.64
-0.29%
-0.29%
1M
|
Health Services
| -0.81%
| O: -0.29%
H: 1.73%
C: 1.59%
olinvyk
agreement
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Published: 2023-11-14
(Crawled : 12:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -34.39%
| O: -5.09%
H: 5.52%
C: 4.19%
business
update
results
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
Published: 2023-11-09
(Crawled : 12:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -31.35%
| O: -2.18%
H: 8.93%
C: 5.36%
financial
results
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
Published: 2023-10-16
(Crawled : 11:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -29.82%
| O: 0.0%
H: 14.27%
C: 7.14%
trv045
favorable
topline
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Published: 2023-10-02
(Crawled : 11:00)
- globenewswire.com
TRVN
|
$0.38
-3.31%
-3.42%
470K
|
Health Technology
| -34.83%
| O: -0.5%
H: 7.15%
C: 1.63%
conference
respiratory
presentation
olinvyk
study
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount